Observational studyNature medicine2020
Development and validation of serological markers for detecting recent Plasmodium vivax infection.
Observational study in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07770048 (The Center for the Study of Complex Malaria in India), which is not on this map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Center for the Study of Complex Malaria in India (CSCMi 3.0): Hidden Plasmodium Infections: Reservoirs, Impact, and Biomarker Discovery
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 156 citations in OpenAlex.
- Malaria in pregnancy in India: a 50-year bird's eye.Frontiers in public health · 2023Pooled it
- Immunodominant B-cell epitopes for precision surveillance ofEmerging microbes & infections · 2026Article
- Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array.PLoS pathogens · 2026Article
- Validation of serological markers of recent exposure toThe Lancet regional health. Western Pacific · 2026Article
- Malaria serology for surveillance, insights into immunity, and vaccine development.Infection and immunity · 2026Review
- Comparative evaluation of four immunoassays for Plasmodium vivax serological detection using recombinant PvMSP1-42 antigen.PLoS neglected tropical diseases · 2026Article
- Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation.The Journal of infectious diseases · 2026Article
- Serological surveillance for malaria elimination in Southeast Asia: a scoping review.Malaria journal · 2026Article
- A rapid immunochromatographic test for antibody detection as a new tool for monitoring malaria caused by Plasmodium vivax.PLoS neglected tropical diseases · 2026Article
- Sub-RDT Plasmodium vivax infections and G6PD deficiency in Kayin State, Myanmar.Malaria journal · 2026Article
- Predictive value of PfEMP1 antibody profiles for the course of controlled human malaria infections.PLoS pathogens · 2026Article
- Assessing the effect of parasite antigen genetic diversity on performance of Plasmodium vivax serological exposure markers for malaria: a multicentre observational diagnostic accuracy study.The Lancet. Microbe · 2026Observational
- High-AltitudeOpen forum infectious diseases · 2026Article
- Whose Line Is it Anyway? Defining Seropositivity Cutoffs for Infectious Disease Surveillance.The Journal of infectious diseases · 2026Article
- Sociodemographic and behavioral determinants of Plasmodium vivax-specific antibody responses among short-term Myanmar migrants in Thailand.Malaria journal · 2026Article
- Unite against Malaria: challenges and achievements in malaria control around the globe.Nature communications · 2026Article
- A longitudinal study of children identifies antibody Fc-mediated functions and antigen targets of immunity to Plasmodium vivax malaria.Immunity · 2026Article
- PTRAMP, CSS and Ripr form a conserved complex required for merozoite invasion of Plasmodium species into erythrocytes.Nature communications · 2026Article
- Heterogeneity of malaria transmission in urban settings in Ethiopia: A seroprevalence and risk factor analysis.PloS one · 2026Article
- Cytokine signatures associated with persistent antibody responses to multipleFrontiers in immunology · 2026Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 13 institutions in 7 countries.
Funding
Abstract
A major gap in the Plasmodium vivax elimination toolkit is the identification of individuals carrying clinically silent and undetectable liver-stage parasites, called hypnozoites. This study developed a panel of serological exposure markers capable of classifying individuals with recent P. vivax infections who have a high likelihood of harboring hypnozoites. We measured IgG antibody responses to 342 P. vivax proteins in longitudinal clinical cohorts conducted in Thailand and Brazil and identified candidate serological markers of exposure. Candidate markers were validated using samples from year-long observational cohorts conducted in Thailand, Brazil and the Solomon Islands and antibody responses to eight P. vivax proteins classified P. vivax infections in the previous 9 months with 80% sensitivity and specificity. Mathematical models demonstrate that a serological testing and treatment strategy could reduce P. vivax prevalence by 59-69%. These eight antibody responses can serve as a biomarker, identifying individuals who should be targeted with anti-hypnozoite therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.